Entry Point Capital, LLC Syndax Pharmaceuticals Inc Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 1,090 shares of SNDX stock, worth $20,819. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,090
Previous 8,636
87.38%
Holding current value
$20,819
Previous $206 Million
89.11%
% of portfolio
0.03%
Previous 0.18%
Shares
3 transactions
Others Institutions Holding SNDX
# of Institutions
202Shares Held
87.1MCall Options Held
268KPut Options Held
76.8K-
Black Rock Inc. New York, NY7.91MShares$151 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.34MShares$140 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.72MShares$109 Million9.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.8MShares$91.6 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.89MShares$74.3 Million1.09% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $1.08B
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...